• Completed A$2.4 million strategic investment from major shareholder ZYBT
• Submitted FDA Type D meeting request for single-pivotal-trial pathway for Elate Ocular®
• Advanced CMC progress, including extended drug substance stability and pathogen inactivation

Cambium Bio Limited (ASX:CMB) released its quarterly cash flow report and business update for the period ending 31 March 2026. Key highlights include the completion of a A$2.4 million strategic investment from major shareholder ZYBT, submission of a Type D meeting request to the FDA seeking concurrence on a single-pivotal-trial registration pathway for Elate Ocular®, and continued progress on the Chemistry, Manufacturing, and Controls (CMC) program, including extended drug substance stability data and development of additional pathogen inactivation steps. The company also provided an updated development timeline for Elate Ocular®, targeting First Patient In in H2 CY 2026, topline data in Q4 CY 2027, and a rolling BLA submission in mid-CY 2028. Cambium Bio's cash position at the end of the quarter was A$2.246 million, supplemented by anticipated future R&D tax incentive refunds, continued royalty income, and ongoing funding initiatives. The company is pursuing a multi-pronged funding strategy to support the pivotal Phase 3 program, including RDTI pre-financing, licensing transactions, and potential additional strategic equity investments.

Cambium Bio is targeting the following key milestones for Elate Ocular®: First Patient In in H2 CY 2026, topline data in Q4 CY 2027, and a rolling BLA submission in mid-CY 2028.

Cambium Bio will continue to advance out-licensing discussions with global ophthalmology partners to unlock additional non-dilutive capital and to establish commercialisation pathways for Elate Ocular®.